Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases
Allergan, Inc. and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.